Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSV versus P-PRP for refractory patellar tendinopathy
2016-001262-28Phase 2Active
- Sponsor
- Institut de Teràpia Regenerativa Tissular
- Start
- Jun 2017
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous expanded bone marrow mesenchymal progenitor cells and platelet-rich plasma in patellar tendinopathy (PT) (2 arms), sponsored by Institut de Teràpia Regenerativa Tissular. Primary endpoints: Tendon regeneration response and Safety and feasibility. Started Jun 2017; status: active.
02
Drugs
autologous expanded bone marrow mesenchymal progenitor cellsplatelet-rich plasma
03
Conditions
patellar tendinopathy (PT)
Beyond the preview
Go deeper on 2016-001262-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001262-28.